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Down syndrome (DS) is a neurodevelopmental disorder caused by having an extra copy of 
the 21st chromosome. It is the most common genetic cause of intellectual disability (ID), occurring 
in 1 in 700 live births. DS involves a variety of phenotypes, but every person with DS exhibits 
muscle weakness and ID. The extra copy of chromosome 21 includes nearly 200 protein-coding 
genes, and causation can be challenging to pinpoint as many elements of cellular biology are 
altered. DS researchers aim to elucidate the genotype to phenotype relationship of the syndrome, to 
explain why having an extra 21st chromosome causes the syndromic effects that it does. 
Many studies of DS have investigated regions of the 21st chromosome at a time, grouping 
genes together by location. However, little is known about the individual genes that make up the 
human 21st chromosome. Establishing which genes contribute to DS could clarify the mechanism 
for the neuromuscular symptoms associated with DS. In attempting to fill this gap, I have worked 
with the laboratory of Dr. Jon Pierce to systematically characterize the genes of the 21st 
chromosome for a potential role in the nervous system or muscle function. 
To this end, the Pierce lab uses the nematode ​Caenorhabditis elegans ​to study orthologs, or 
equivalent genes, from the human 21st chromosome. The general approach is to identify genes 
conserved between human and ​C. elegans ​and conduct broad, unbiased screens to identify 
potentially important genes. ​C. elegans ​can be a useful model for taking this approach to DS, as it has 
been used to discover the function of hundreds of genes in the nervous system and muscle in 
humans and shares orthologs with many of the protein-coding genes on our 21st chromosome. 
We first conducted a loss-of-function screen, taking the ​C. elegans ​genes and systematically 
“breaking” them to observe phenotypic defects. The ​C. elegans ​loss-of-function mutants underwent 
a series of behavioral and pharmacological assays to evaluate phenotypic defects. The 
loss-of-function screen resulted in the identification of 10 genes thought to be critical for synaptic 
or motor function. Several of these genes were not previously identified for a contribution to DS. 
We have since begun a gain-of-function screen using similar behavioral tests to empirically 
determine which genes are problematic when overexpressed. Preliminary results implicate a few 
genes in disrupting neuron-to-muscle circuitry. I have also verified transcriptional overexpression 
in mutants relative to control strains. 
I aim to provide a more complete understanding of the individual genes involved in 
DS-associated phenotypes. Doing so can provide a foundation for other DS researchers and inform 
efforts toward a more precise mechanism of action. The hope is that these genes might later serve 
as therapeutic targets for alleviating neuromuscular symptoms in people with DS.  
Introduction 
Down syndrome (DS) is caused by a complete or partial trisomy of the 21st chromosome. 
DS is the most frequent survivable autosomal aneuploidy and leads to lifelong cognitive 
impairment. Each person with DS experiences phenotypes of intellectual disability (ID), such as 
learning and memory challenges, and muscle weakness which can make it difficult to speak and 
move efficiently. Other phenotypes with incomplete penetrance include heart defects, childhood 
leukemia, and early-onset Alzheimer’s disease. Interestingly, people with DS have a lower risk of 
developing solid tumors (Antonarakis et al., 2020). 
It was discovered over 60 years ago that DS is caused by an extra copy of the 21st 
chromosome (Human somatic autosome 21, HSA21), but it is unclear why the extra genetic 
material leads to DS. Each theory discussed here has merits and shortcomings, and it is likely that 
the connection between trisomy 21 and DS contains elements of both. One theory suggests that DS 
symptoms are caused by the cellular strain that results from extra genetic material (Patterson, 
2009). It is true that there are direct and indirect disruptions on the rest of the genome and on 
cellular and tissue function. For example, trisomy of HSA21 causes global DNA hypermethylation on 
other chromosomes, which can affect the transcription of numerous genes (Antonarakis et al., 
2020). However, comparing partial trisomies has shown that the degree of symptoms is not 
explained by the amount of extra genetic material (Lyle et al., 2009). 
Another theory held that a “Down Syndrome Critical Region” (DSCR) that contains a select 
group of genes is responsible, rather than the burden of the chromosome itself. The DSCR theory 
was formed after mapping the area of chromosomal overlap between two partial trisomic patients 
that had DS, which resulted in a region of about 30 genes. Some evidence supports this theory as 
well. The Ts1Rhr mouse model, only trisomic for genes representing the human DSCR, displayed 
similar phenotypes to the Ts65Dn model that is trisomic for larger chromosomal regions 
(Belichenko et al., 2009). However, another study found that the Ts1Rhr trisomic DSCR genes are 
necessary, but not sufficient, to achieve the structural changes seen in Ts65Dn mice brains (Olson et 
al., 2007). Additionally, the partial trisomies of 30 people with DS were aligned, and there was not a 
region of overlap that invariably led to DS (Lyle et al., 2009). Despite agreement that the DSCR is 
likely to contain a few critical genes, the field lacks a broad consensus about the theory because the 
DSCR alone does not explain all symptoms. A recent study in favor of a more narrow region, the 
Highly Restrictive DSCR, renewed conversations about this theory (Pelleri et al., 2019). 
Much of the foundational DS research was conducted in mouse models. Many useful models 
exist, such as the broadly used Ts65Dn mouse model of DS and a recent humanized mouse model 
that contains a nearly complete long arm of HSA21 (Kazuki et al., 2019). However, most of the work 
done in mice has looked at regions of the chromosome or sets of genes at a time. It can be beneficial 
to investigate individual genes through loss-of-function or gain-of-function analyses to dissect the 
genetic basis for a particular phenotype. It is also much simpler to design targeted therapeutics 
when there are individual candidate genes rather than large chromosomal regions. ​C. elegans ​is a 
useful model for conducting genetic screens, as it is simple to manipulate individual genes and 
conduct matings to achieve genetic crosses (Brenner, 1974). 
The genetic screens we conducted in ​C. elegans ​are among the first efforts to systematically 
characterize genes on HSA21. Around the time of our loss-of-function screen, a systematic 
overexpression screen was conducted using HSA21 cDNAs in zebrafish embryos to identify 
developmental mutants (Edie et al., 2018). The work from the ​C. elegans ​and zebrafish studies has 
provided insight into gene function and identified genes that can be prioritized in future DS 
research.  
 
Materials and Methods 
Some descriptions that are relevant to the loss-of-function screen have been adapted from 
Nordquist et al., 2018. 
Worm maintenance  
C. elegans ​nematodes were kept at room temperature (~20℃) on an NGM (nematode 
growth media) agar plate seeded with an ​E. coli ​OP50 bacterial lawn. The N2 Bristol strain was used 
as the reference wild-type strain. Plates were regularly propagated to prevent starvation. 
Identification of Orthologs 
There are around 200 protein-coding genes on HSA21, and 165 genes remain after 
removing those that encode keratin. The initial list of orthologs was created using OrthoList, which 
reported 85 putative orthologs. Candidate orthologs were analyzed using InParanoid algorhythms, 
which predicts the human-to-worm relationship. All putative orthologs were considered for 
investigation except those within many-to-many relationships (many potential human genes 
corresponding to many potential ​C. elegans ​genes).  
Loss-of-Function Screen 
Ultimately, we investigated 51 tightly-conserved ​C. elegans ​genes that correspond to 47 
human genes. Loss-of-function mutant strains were obtained through the National BioResource 
Project (NBRP) and Caenorhabditis Genetics Center (CGC). Mutants underwent the following assays 
(described below): long-term locomotion, short-term locomotion, pharyngeal pumping, aldicarb 
sensitivity, and levamisole sensitivity. All behavioral assays were conducted blind to the worms’ 
genotype. 
Overexpression Screen 
Orthologs are cloned into plasmids and injected directly into eggs of adult worms. The 
plasmids are expressed as extrachromosomal arrays and contain an mCherry reporter as the 
co-injection marker. F1 worms are isolated and propagated for experimentation if they reliably 
express the red marker. To date, 30 overexpression strains are available, covering 9 of the HSA21 
orthologs injected at low and intermediate concentration and 8 control strains that only contain the 
co-injection marker. Long-term locomotion and egg retention assays have been performed 
(described below). Verification of transcriptional overexpression is conducted using qRT-PCR. 
Long-term Locomotion / Exploration Assay 
A single L4-stage worm is placed on a 3.5-cm diameter plate seeded with a thin, uniform 
bacterial lawn. The worm freely roams the plate for a 16-hour period. The tracks left in the lawn are 
compared against a grid system to measure the number of squares entered by the worm. This assay 
provides a read-out not only of general motor ability but also sensorimotor integration. 
Short-term Locomotion / Radial Dispersion Assay 
Five to eight worms are placed in the center of a 10-cm diameter plate seeded with a 
uniform bacterial lawn and allowed to disperse for 10 minutes before displacement is measured. 
This assay evaluates general motor abilities. 
Pharyngeal Pumping Assay 
Pharyngeal pumping rate of day one-staged adult worms was observed by counting the 
number of pumps in a 30-second time period. 
Aldicarb Sensitivity Assay 
Aldicarb is an acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine 
in the synapses. In the presence of aldicarb, acetylcholine is not degraded and is thus able to 
constitutively activate the cholinergic receptors in muscle, causing paralysis. Aldicarb sensitivity 
was measured as described (Mahoney et al., 2006). Worms were placed on a 1-mM aldicarb plate 
and scored for paralysis every half hour for 3 hours. Worms were considered paralyzed when they 
did not spontaneously move and did not respond to prodding. 
Levamisole Sensitivity Assay 
Levamisole is a cholinergic receptor agonist. It constitutively activates the cholinergic 
receptors in muscle, causing paralysis if the receptors are working properly. Levamisole sensitivity 
was measured as described (Lewis et al., 1980). Day-one adult worms were placed on 800 µM 
Levamisole plates and scored for paralysis every 10 minutes for 1 hour. 
Egg Retention Assay 
A single adult worm is placed in a 20% bleach solution. This concentration dissolves the 
adult but leaves intact the eggs, which are then counted. Proper egg-laying requires regulated 
coordination between neuronal and muscular elements near the vulva. 
qRT-PCR 
Transcriptional overexpression of orthologs is assessed using qRT-PCR. RNA is isolated 
from crowded plates using a freeze-thaw technique. RNA is extracted using the Invitrogen RNA 
extraction kit and protocol. Following purification, I conduct reverse transcriptase (RT)-PCR using 
the ProtoScript II First Strand cDNA Synthesis Kit standard protocol. I conduct qPCR using SYBR 
Green according to the two-step protocol by Applied Biosystems. I optimized primer concentrations 
at 3.0 µL of 5 µM for both primers. Relative fold gene expression is quantified using the ΔΔC​T 
method. The housekeeping gene ​pmp-3 ​is used as the reference gene. Each gene expression 








Figure 1. Results from the short-term locomotion assay in loss-of-function mutants. 
 
Figure 1. Results from the short-term locomotion assay in loss-of-function mutants. A. Displacement 
in mm by mutant genotype relative to wild-type N2. Three genotypes resulted in significantly 
reduced displacement: unc-26, cysl-2, mt-1. B. Displacement in mm by mutant genotype or restored 
genotype. The motor defect was rescued for both cysl-2 and mt-1 when given a functional copy of 














Figure 2. Results from the long-term locomotion assay in loss-of-function mutants.  
 
Figure 2. Results from the long-term locomotion assay in loss-of-function mutants. A. Percent 
squares entered by mutant genotype. Many genotypes were “dwellers” relative to wild-type, near 
the “dweller” control tax-4: unc-26, eva-1, dnsn-1, mtq-2, pdxk-1. B. Percent squares entered by 
mutant genotype or restored genotype. The motor defect was rescued in at least one restorative 

















Figure 3. Results from pharyngeal pumping assay for loss-of-function mutants. 
 
Figure 3. Results from pharyngeal pumping assay for loss-of-function mutants. A. Pumps per minute 
by mutant genotype. Several genotypes have a significantly reduced pumping rate: unc-26, 
B0024.15, mtq-2, pad-2, ncam-1, and cle-1. B. Pumps per minute by Genotypes mtq-2, pad-2, 
ncam-1, and cle-1. Each of the restorative genotypes resulted in rescuing the defective pumping. 



















Figure 4. Results from the aldicarb assay for loss-of-function mutants. 
 
Figure 4. Results from the aldicarb assay for loss-of-function mutants.​ ​A. Percent moving on 
aldicarb plates over time. Genotypes unc-26, mtq-2 (ok3740 and tm3565 alleles), and pdxk-1 
mutants showed significant resistance to paralysis relative to wild-type. B. Percent mobile on 
aldicarb at the 180-minute time point by genotype. There is significant resistance to paralysis in 
pdxk-1, mtq-w, and unc-26 genotypes. These data are modified from Figure 5 in Nordquist et al., 
2018. 
Figure 5. Results for aldicarb and levamisole assays for mtq-2, pdxk-1, and unc-26 mutant and 
restored genotypes. 
 
Figure 5. Results for aldicarb and levamisole assays for mtq-2, pdxk-1, and unc-26 mutant and 
restored genotypes. A. Aldicarb results for mtq-2 mutant. Green lines indicate mtq-2 mutants, 
which were resistant to paralysis by aldicarb. Blue indicates the restoration of the tm3565 allele, 
which rescued the sensitivity back to wild-type levels. B. Levamisole results for mtq-2. Mtq-2 
mutants are sensitive to paralysis by levamisole. C. Aldicarb results for pdxk-1. Pdxk-1 mutants 
were resistant to paralysis by aldicarb, and this defect was rescued to wild-type levels. D. Pdxk-1 
mutants are hyper-sensitive to paralysis by levamisole. E. Unc-26 mutants are resistant to paralysis 
by aldicarb. F. Unc-26 mutants are hyper-sensitive to paralysis by levamisole. These data are 



























Figures 6 and 7. Current results for behavioral assays for ​C. elegans ​overexpressing HSA21 
orthologs. 6. Egg retention in overexpression strains. Four out of five strains have a significantly 
low number of eggs retained relative to wild-type. 7. Long-term locomotion in overexpression 
strains. So far, none of the overexpression mutants vary significantly from wild-type in long-term 
locomotive ability. 
 
Figure 8. Determining co-localization of MTQ-2 in synapses. 
 
Figure 8. Determining co-localization of MTQ-2 at synapses. A. MTQ-2 colocalizes with 
acetylcholinergic synapses. Pmtq-2::mCherry colocalizes with ACh::GFP expression. B. MTQ-2 does 
not colocalize with GABAergic synapses. Pmtq-2::mCherry does not colocalize with GABA::GFP. 
These data are modified from Figure 7 in Nordquist et al., 2018. 
 
Figure 9. Preliminary results for transcriptional overexpression from qRT-PCR.  
Ortholog overexpressed Relative to N2 Background Relative to C5 Background 
Cct-8​ - High concentration 415.4 36.7 
Cct-8​ - Medium concentration 75.4 6.7 
Cct-8​ - Low concentration 28.8 2.5 
Mtq-2​ - Low concentration 26.8 165.5 
Mbk-1​ - Medium concentration 409.2  
Figure 9. Preliminary results for transcriptional overexpression from qRT-PCR. These data are 
generated using the ΔΔC​T​ method for relative quantification. Transcriptional overexpression is 
confirmed in cct-8, mtq-2, and mbk-1 overexpression strains relative to both N2 and C5 control 
backgrounds using pmp-3 as the reference gene. Relative overexpression varies widely but 
indicates successful overexpression of the transgenes. 
 
Discussion 
Our research represents one of the earliest attempts to characterize individual genes on the 
human 21st chromosome. We have identified several candidate genes that could contribute to 
DS-associated phenotypes by examining the orthologs in ​C. elegans. ​Our loss-of-function screen 
identified 10 genes that are critical for neuron or muscle function: ​ncam-1, eva-1, cle-1, unc-26, 
cysl-2, rnt-1, pad-2, dnsn-1, pdxk-1, ​and ​mtq-2. ​Critical mutants were identified by defects in the 
behavioral assays (Fig. 1-3) and the pharmacological assays (Fig. 4-5), and our work was published 
in ​G3: Genes, Genomes, Genetics ​(Nordquist et al., 2018). ​The results of the screen confirmed deficits 
for well-studied genes but also revealed roles for previously unstudied genes in neuron or muscle 
function.​ Performing a broad, unbiased screen of all available HSA21 orthologs enabled us to 
implicate previously unstudied genes in contributing to DS-associated phenotypes. 
Figures 4 and 5 show the results for the aldicarb and levamisole assays. Aldicarb, the 
acetylcholinesterase inhibitor, prevents degradation of acetylcholine in synapses and leads to 
paralysis by over-stimulation of muscle. Three of the mutant genotypes (​mtq-2, unc-26, ​and​ pdxk-1​) 
were resistant to paralysis by aldicarb, with worms maintaining mobility on aldicarb plates longer 
than wild-type. This either indicates that mutants have less acetylcholine released into synapses or 
have an issue with receptor binding to acetylcholine. The levamisole assay was conducted to clarify 
whether the mutants had pre- or post-synaptic defects. Levamisole is a cholinergic receptor agonist, 
so it triggers paralysis by over-stimulating muscle when the postsynaptic receptors work properly. 
The three mutants were all found to be sensitive or hypersensitive to paralysis by Levamisole, 
indicating that resistance to aldicarb is caused by defects in presynaptic neurotransmitter release. 
Further investigation of ​mtq-2 ​verified that it is expressed throughout the worm’s nervous system 
and colocalized to cholinergic synapses (Fig. 8), which suggests its promise as a potential 
contributor to neuromuscular symptoms experienced in DS. 
Preliminary results from the overexpression screen are shown in Figures 6 and 7. Of the 5 
strains examined thus far, 4 display significant reduction in egg retention and none display defects 
in long-term locomotion. Fewer retained eggs could indicate hyperactive neurotransmission within 
the egg-laying pathway, or could be due to developmental defects that lead to reduced or delayed 
egg production. We plan to assess both egg-laying behavior and gross developmental defects 
moving forward. To verify the overexpression of the transgenic arrays, I began conducting qRT-PCR 
on overexpression strains relative to N2 wild-type background and the C5 control background that 
expresses the co-injection marker mCherry. Relative overexpression of each target gene varies 
significantly, but we satisfied our goal of confirming the overexpression of the desired genes. 
We have identified genes that are critical for neuromuscular function through the 
loss-of-function screen, and now we aim to identify the orthologs that are problematic when 
overexpressed. These genes are promising candidates for driving DS-associated phenotypes like 
muscle weakness and intellectual disability. Our work in ​C. elegans ​examines the genetic basis for 
DS-associated phenotypes at the level of individual genes, which provides a necessary complement 
to the foundational studies in other model systems. By characterizing the functions of candidate 
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